Tag - THTX

Developments

Theratechnologies reduces R&D headcount on sales shortfall

With sales falling short of expectations, Theratechnologies (TSX:TH; NASDAQ:THTX) is reducing its R&D head count. Second quarter revenue fell 8.9% to $17.5-million (U.S.) from $19.3-million a year ago. “Second...

July 12, 2023

Markets

Cantor starts Theratechnologies at OW; PT $9

Cantor Fitzgerald launched coverage of Theratechnologies (NASDAQ:THTX) with an “overweight” rating and $9 price target. The stock closed at $1.88 on Nov. 16. “We believe the peak sales potential of Theratechnologies’...

November 17, 2022

Markets

Mackie Research ups Theratechnologies to buy; holds PT at $6.50

Mackie Research upgraded Theratechnologies (TSX:TH; NASDAQ:THTX) to “buy” from “hold” but maintained its price target at $6.50 (Canadian), saying the current share price represents a favorable risk-reward situation...

December 11, 2019

Tag - THTX

Theratechnologies reduces R&D headcount on sales shortfall

Cantor starts Theratechnologies at OW; PT $9

Mackie Research ups Theratechnologies to buy; holds PT at $6.50

General

More